Health-related quality of life in patients with newly diagnosed type 1 diabetes by Hart, HE et al.
  
 University of Groningen
Health-related quality of life in patients with newly diagnosed type 1 diabetes
Hart, HE; Redekop, WK; Meyboom-de Jong, B; Bilo, HJG
Published in:
Diabetes Care
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2003
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Hart, HE., Redekop, WK., Meyboom-de Jong, B., & Bilo, HJG. (2003). Health-related quality of life in
patients with newly diagnosed type 1 diabetes. Diabetes Care, 26(4), 1319-1320.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the










S erum IGF-I is reduced in adoles-cents with type 1 diabetes, and in-jections of IGF-I improve glycemic
control (1). The fact that sulfonylureas
can increase IGF-I directly and indepen-
dent of insulin has not been included in
standard literature (2). The first observa-
tion of a stimulatory effect on serum IGF-I
was made in hypophysectomized rats (3).
In in vitro experiments, glibenclamide
stimulated growth of human chondro-
cytes via IGF-I and independent of insulin
(4). Glibenclamide and glimepiride had
dose-dependent stimulatory effects on
IGF-I transcription and production in hu-
man liver cells (HuH7) (5).
We recruited 40 pubertal patients
with type 1 diabetes of a duration of 1
year (negative for C-peptide) at Ulm (n
20) and Bern (n  20). They were ran-
domly allocated at the start of treatment
and each participant underwent a 6-week
course of either glimepiride (one daily
dose of 8.2 mol  4 mg; n  20) or
placebo (n  20) in addition to the mul-
tiple injection intensive insulin therapy
(Table 1). One patient receiving glimepi-
ride was withdrawn because of viral en-
cephalitis. The primary end point in our
study had been defined as the increment
of IGF-I between start of treatment and
6–8 weeks thereafter. Assuming a SD of
200 ng/ml, we estimated that in a two-
sided statistical test with an level of 0.05
and a power of 80%, sample sizes of 17
patients per group would be sufficient to
attain a significant result, if a true rise in
IGF-I from 300 ng/ml (5th percentile) to
500 ng/ml (50th percentile) occurred.
The study protocol was approved by the
local ethics committees at both centers.
At the time of allocation, both groups
were not relevantly different regarding
age, sex, weight, height, blood pressure,
insulin dose, fasting serum glucose, hypo-
glycemic events, IGF-I, IGF binding pro-
tein-3 (IGFBP-3), HbA1c, or serum lipids.
No remarkable changes (Mann-Whitney
U test) in IGF-I or IGFBP-3 could be ob-
served during glimepiride treatment (Ta-
ble 1). When compared with the placebo
group, no differences could be found.
Glimepiride did not influence weight,
blood pressure, insulin dosage, fasting
serum glucose, rate of hypoglycemias,
HbA1c, or serum lipids.
In adolescents with type 1 diabetes,
the peripheral mode of application of in-
sulin is likely to lead to IGF-I insuffi-
ciency, consecutively to growth hormone
hypersecretion and an insulin-resistant
state. In case oral sulfonylureas could
effectively increase IGF-I, they could pre-
sent a suitable therapeutic option because
they are inexpensive, easy to administer,
and do not endanger patients by hypogly-
cemias. An increase of IGF-I to the upper
normal range would be desirable and
would not likely be associated with severe
side effects (6).
For safety reasons, glimepiride,
which exhibited a higher stimulatory ef-
fect on IGF-I than glibenclamide (5), was
given at a usual dose. We anticipated that
a treatment duration of 6 weeks should be
sufficient to induce a change in IGF-I. The
reason why IGF-I did not increase signif-
icantly probably lies in the low serum
concentrations of glimepiride (median
0.16 mol/l) achieved with our protocol.
Glimepiride levels were up to four times
higher in the cell culture experiments (5).
The authors consider it appropriate to
suggest further studies using higher con-
centrations of sulfonylureas.
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Table 1—Serum concentrations of IGF-I and IGFBP-3 in pubertal patients with type 1 diabetes receiving a 6-week course of either glimepiride
(G) or placebo (P)
Treatment n Age 7 0 1 7
IGF-I [ng/ml] G 19 14.0 (11.9–16.3) 383 (85–675) 388 (117–600) 402 (110–677) 434 (124–572)
P 20 14.3 (12.0–17.3) 377 (227–567) 385 (224–750) 379 (226–584) 380 (209–597)
IGFBP-3 [mg/l] G 19 14.0 (11.9–16.3) 4.3 (2.2–5.9) 4.6 (2.7–5.9) 4.5 (2.6–5.3) 4.5 (2.8–6.3)
P 20 14.3 (12.0–17.3) 4.5 (3.0–5.7) 4.7 (2.9–5.7) 4.9 (3.1–5.6) 4.6 (3.0–5.8)
Where applicable, medians and ranges are given. The patients were studied 6–8 weeks before treatment (“7”), at the start of treatment (“0”), 1 week after (“1”),
and 6–8 weeks after start of treatment (“7”).
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S ilent myocardial ischemia (SMI) iscommon in patients with diabetes(1–4). The prognostic value of SMI,
evidenced by exercise electrocardiogram
(ECG) stress test (5) and thallium 201
myocardial scintigraphy (6), as well as
their association (7) in asymptomatic di-
abetic patients, has recently been demon-
strated. About 50% of the patients with
SMI exhibit angiographically normal cor-
onary arteries (1,2). In these patients, en-
dothelial dysfunction and abnormalities
of coronary microcirculation may be in-
volved (8). So far, the respective roles
played by these functional disorders, by
the demonstrated silent coronary steno-
ses, or by both in the poor prognosis of
SMI are still unknown.
The aim of this study was to deter-
mine the prognostic value of silent coro-
nary stenoses in patients with diabetes.
We prospectively recruited 362 asymp-
tomatic patients with diabetes, without
prior myocardial infarction, with at least
one additional risk factor, and with a nor-
mal resting ECG. All of them underwent a
myocardial scintigraphy after an exercise
or a pharmacological (dipyridamole infu-
sion) stress test to detect SMI. The pa-
tients with SMI subsequently underwent
a coronary angiography to detect coro-
nary stenosis, as previously reported (2).
A total of 345 (95.3%) patients were fol-
lowed-up for 41  24 months (mean 
SD) with regard to the occurrence of ma-
jor cardiac events (death of cardiac origin,
myocardial infarction, unstable angina,
heart failure, and secondary need for cor-
onary revascularization).
The diabetic patients (190 men and
172 women, 10 type 1 and 352 type 2
diabetes) were 58.5  9.1 years of age.
The prevalence of peripheral or carotid
occlusive arterial disease was 6%. There
was evidence of SMI in 121 (33.4%) pa-
tients. A coronary angiography was per-
formed in 92 subjects (44 had significant
coronary stenoses [70%]). A major car-
diac event occurred in 23 patients (3 car-
diac deaths, 11 myocardial infarctions, 5
unstable angina, 3 congestive heart fail-
ures, and 1 noninitial revascularisation
procedure). The rate of silent coronary
stenoses was significantly higher in the
patients with major cardiac events than in
those without (13/23 [57%] vs. 29/322
[9%]), with an odds ratio of 13.1 (95% CI
5.3–32.6, P  0.001). SMI (3.6 [1.5–
8.5], P 0.003) and peripheral or carotid
occlusive arterial disease (3.8 [1.1–12.3],
P  0.049) were less strong predictors of
major cardiac events. The traditional car-
diovascular risk factors, even combined,
were not predictive of major cardiac
events. According to the Kaplan-Meier
analysis, a major cardiac event occurred
in 30.9% of the patients with SMI and
coronary stenoses, 1.4% of the patients
with SMI but without coronary stenosis,
and 4.0% of the patients without SMI (log
rank 42.5, P  0.0001) (Fig. 1).
This study shows for the first time
that 1) the presence of silent coronary ste-
noses with SMI is the main predictive fac-
tor for subsequent major cardiac events in
diabetic patients and 2) patients with a
normal myocardial scintigraphy and
those with an abnormal scintigraphy but
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a Type 1 Diabetic
Patient
A case for late autoimmune
diabetes of the adult?
T ype 1 diabetes is a well-defined con-dition requiring life-saving insulinreplacement therapy immediately
after diagnosis (1). It is also a well-known
fact from the natural course of the disease
that soon after the insulin therapy has
been initiated, insulin requirements de-
crease, sometimes rapidly, and patients
who stopped taking insulin shortly after
diabetes diagnosis have been reported
(2). However, this so-called “honeymoon
period” usually starts several weeks after
the diagnosis and rarely exceeds several
months’ duration. It is believed, however,
and has been unfortunately shown in the
past, e.g., during wartime, that insulin
discontinuation in a long-standing type 1
diabetic patient poses a serious threat to
health and life (3,4). We describe a case of
a patient with a definite diagnosis of au-
toimmune diabetes who, 2 years after
having been diagnosed with diabetes,
stopped insulin treatment for a period of
17 months and did not develop
ketoacidosis.
In April 2000, a 19-year-old woman
was admitted to the Metabolic Diseases
Department due to profound weakness,
dizziness, and increased thirst, as well as a
10-kg weight loss in 6 months. The symp-
toms occurred several months earlier but
became more severe within the previous 8
weeks.
The patient was diagnosed with type
1 diabetes in November 1998. Her symp-
toms at the time gradually developed for 4
months and included increased thirst,
polyuria, weight loss, and mild ketoaci-
dosis. At the time of diagnosis, her blood
glucose was 17.8 mmol/l. She was posi-
tive for islet cell autoantibodies (ICAs),
with a titer of 90 JDF units, as well as
positive for antibodies against GAD (anti-
GAD, 80 units/ml). The treatment on dis-
charge consisted of an intensive insulin
regimen: short-acting insulin before
meals and long-acting insulin twice daily;
the daily requirement of insulin was 46
units.
The patient continued with her treat-
ment for the next 2 years. She was com-
pliant with physician recommendations,
adhered to a prescribed diet, and per-
formed self-monitoring of blood glucose
four to six times daily. Her mean daily
blood glucose ranged from 5.6 to 11.1
mmol/l. However, in November 2000,
the patient stopped taking insulin and
went on a free diet. The immediate cause
of the sudden change of her behavior was
a deep conflict with her parents, which
eventually led to her leaving home for 13
months. During this time, she, using her
words, “was well and completely forgot
about her diabetes.” In December 2001,
she returned to her parents, although she
refused to restart insulin therapy or to have
a therapeutic session with a psychologist.
When she was admitted to our de-
partment in April 2002, her blood glucose
was 29.8 mmol/l. It was established that
she had not been taking insulin for the
previous 17 months, nor had she been
measuring her glucose or following any
diet. Her body mass was 53 kg, height
165 cm, BMI 19.5 kg/m2, and blood pres-
sure 120/80 mmHg. No abnormalities in
physical examination were found. Her
acid-base balance was pH 7.44, serum bi-
carbonate 20 mmol/l, and base excess
2.8 mmol/l; she also had a trace of ke-
tones in her urine. Her HbA1c was 10.6%
and C-peptide 0.21 nmol/l (reference
range 0.17–1.2). As at diabetes diagnosis,
she was positive for ICAs and anti-GAD,
although the titers of these autoantibodies
were distinctly lower: 10 JDF units and
5.8 units/ml, respectively. In the begin-
ning, she was treated with intravenous in-
sulin infusion with a mean daily insulin
requirement of 	90 units and, after 3
days, transferred to a basal-bolus insulin
regimen. At discharge, she was taking 70
units of insulin daily; she was well and
accepted reinitiated insulin therapy.
We present a case of a patient diag-
nosed with type 1 diabetes in whom long-
term insulin discontinuation did not
result in acute hyperglycemic crises. The
diagnosis of type 1 diabetes seems to be
valid, because the immunologic tests con-
firmed that autoimmunologic processes
developed in the patient (1). However,
lack of severe (or, for that matter, any clin-
ically significant) ketoacidosis during dis-
continuation of insulin is somewhat
surprising. The clinical course of the dia-
betes was typical of type 2 rather than
type 1 diabetes (5). Seventeen months
free of insulin therapy suggested that the
patient still had residual insulin secretion
sufficient to maintain effective glucose
metabolism. It is particularly worth not-
ing that autoantibody assays failed to
identify that she required insulin to main-
tain her life. The period of not taking in-
sulin cannot be, however, labeled a
“honeymoon period” since the patient
was treated with stable doses of insulin for
the previous 2 years. The clinical course
of the disease is probably most typical of
late autoimmune diabetes of the adult
Letters
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(LADA), which probably should have
been diagnosed in the patient (6). LADA
has recently gained considerable interest
among both researchers and clinicians,
probably due to increasing availability of
immunological assays (7,8). However, its
clinical identification is still unclear, as
even the issue of insulin requirement at
diagnosis is still a matter of dispute
(9,10). The results of several studies indi-
cate that LADA patients might constitute
up to one-third of the alleged type 2 dia-
betic population (6,7,9), and the aberrant
course of diabetes should always make
one consider LADA as a possible diagnos-
tic option, particularly in younger sub-
jects (7–9).
Discontinuation of insulin treatment
is not an uncommon event in diabetes
therapy (11,12). HsinYu et al. (11) re-
cently identified three predictors of ceas-
ing insulin therapy: age 40 years at
diabetes diagnosis, severe diabetic keto-
acidosis as a first symptom, and excessive
body weight. We have raised the issue of
infection at the moment of diabetes diag-
nosis as another possible predictor of
nonrequirement for insulin in further
therapy (12). However, none of the above
factors were present in our patient.
In our opinion, two conclusions can
be drawn from the case. First, despite
years of intensive research, pathophysiol-
ogy of diabetes is still far from being clear,
as even type 1 diabetes seems to be a het-
erogenous disease. Our patient was devel-
oping diabetic symptoms relatively
slowly, and had it not been for her age and
slim build, she could well have been re-
garded as a type 2 diabetic subject. Sec-
ond, the presence of autoantibodies
typical of autoimmune diabetes may not
definitely lead to the diagnosis of type 1
diabetes because many patients with type
2 diabetes may also present with some
features of autoimmunity. Therefore,
finding clear, unequivocal criteria for dif-
ferentiation between type 1 and type 2
diabetes seems to be the urgent issue of
utmost importance.
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In 1994, we documented a high fre-quency of complicated posttreat-ment neuropathy in patients with
mitochondrial diabetes associated with
tRNALeu(UUR) mutation at position 3243

(MDM3243) (1). Thereafter, experimen-
tal studies accumulated evidence that mi-
tochondria are a major culprit in the
initiation and development of complica-
tions of diabetes through oxidative stress
or altered redox changes (2–4). We re-
cently confirmed our previous observa-
tion on the association of mitochondrial
DNA (mtDNA) mutation with clinical
symptoms of diabetic distal polyneurop-
athy by conducting a large-scale study. A
total of 271 Japanese patients with type 2
diabetes at Saiseikai Central Hospital
were subjected and divided into two
groups. Patients who had leg symptoms
not only at the time of this study, but also
in their history were regarded as positive
and were classified into group 1. Symp-
tomatic neuropathy was assessed by the
presence of one, two, or all of the follow-
ing symptoms over a previous 5-year pe-
riod: numbness in the feet, pricking
sensation in the feet, and deep or burning
pain in the legs. Subjects without these
subjective symptoms were classified into
group 2. The definition of neuropathy
was based on criteria for the diagnosis of
diabetic polyneuropathy, proposed by
the committee for discussing diabetic
neuropathy in Japan (5). Detection of the
3243 mtDNA mutation was performed by
integrating two methods (PCR /restriction
fragment–length polymorphism [RFLP]
and allele-specific PCR amplification),
which improve the sensitivity of detecting
the mutation in leukocytes (6). The detec-
tive threshold of finding heteroplasmy de-
gree is as small as 0.2%. The details of this
integrated methodology have been de-
scribed previously (7).
In result, of 271 subjects 11 were
found to have the 3243 mtDNA mutation,
a frequency of 4.1%. All showed clinical
differences from the syndromes of
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MELAS (mitochondrial encephalopathy,
lactic acidosis, and stroke-like episodes),
CPEO (chronic progressive external oph-
thalmoplegia), and MERRF (myoclonic
epilepsy associated with ragged red fi-
bers). Among all subjects, 91 were as-
signed to group 1 and 180 to group 2. In
group 2, two were found to have the 3243
mutation, and the frequency of finding
the mutation was 1.1%. In group 1, nine
were found to have the 3243 mutation,
and the frequency of finding the mutation
was 9.8%, which was significantly higher
than that of group 2 (P  0.001 by 2
analysis). Thus, the 3243 mtDNA muta-
tion is frequently found among diabetic
patients with symptomatic polyneurop-
athy (group 1). Additionally, patients of
group 1 had earlier onset of diabetes and a
higher frequency of retinopathy, ne-
phropathy, and insulin therapy (data not
shown here).
Oxidative stress may be the leading
proposed mechanism for understanding
the relation fully, because reactive oxygen
species is associated with a number of
pathological conditions of diabetes. Low
et al. (2) hypothesized that lipid peroxi-
dation under hyperglycemic conditions
causes mtDNA mutations that increase
oxygen radicals, causing further damage
to mitochondrial respiratory chain, ulti-
mately resulting in sensory neuropathy.
Interestingly, the 3243 mtDNA mutation
itself increases intracellular reactive oxy-
gen species production (8), which may in
turn cause secondary somatic mutations
in diabetes, making a vicious cycle (9).
Therefore, we speculate that in diabetic
patients with high oxidative stress, when
the effective mechanism for maintaining
mitochondrial function is lacking, the vi-
cious cycle of oxidative stress with in-
crease of the 3243 mtDNA mutation may
be facilitated. Furthermore, when pa-
tients have a certain amount of innate
3243 mtDNA mutation inherited from
the mother, the disadvantage renders the
patients all the more susceptible to oxida-
tive stress under hyperglycemia, thereby
precipitating the vicious cycle and pro-
ducing symptomatic neuropathy.
The frequency of finding the 3243
mtDNA mutation in this study was 4.1%
in total. This frequency is higher than the
reported data of other researchers in Jap-
anese subjects (6,10). One reason for this
is because Saiseikai Central Hospital is the
Diabetes Centers where patients with
complications are likely to be referred to
from local clinics, thus the hospital bias
may have increased the frequency of find-
ing the 3243 mtDNA mutation. The sec-
ond plausible reason is that in this study,
the detective threshold of finding hetero-
plasmy degree for the 3243 mtDNA mu-
tation is more sensitive than that of other
researchers, where the detected threshold
is 	1% (6,10). This highly sensitive
methodology (7) decreases the number of
overlooked patients carrying a very small
degree of heteroplasmy, which in turn
leads to the increased frequency of find-
ing the mutation.
In conclusion, sensory neuropathy in
diabetes is associated with the 3243
mtDNA mutation. This result of human
study supports the recent evidence of ex-
perimental studies (2,3). However, fur-
ther studies are needed to reveal the
association of sensory neuropathy with
more varieties of mitochondrial DNA ab-
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Exercise in Type 1
Diabetes
Maintenance of near euglycemia
despite a drastic decrease in insulin
dose
In patients with type 1 diabetes, hypo-glycemia or degradation in blood glu-cose control may occur during and
after physical exercise (1–3). This may be
avoided in patients with good glycemic
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control by decreasing insulin doses
and/or ingesting carbohydrate. Although
most sport activities involve intense mus-
cle exercise, current recommendations
are based on studies on moderate exercise
(4). We therefore investigated the effect of
a drastic reduction in insulin dose before
a 60-min high-intensity cycle exercise in
12 subjects with uncomplicated type 1 di-
abetes (age 32  7 years, BMI 23  7
kg/m2, HbA1c 7.2  3.8%, and VO2max
40 27 ml min1  kg1 [mean SD]).
Six patients were treated with three daily
injections (regular insulin in the morning
and at noon and mixed regular NPH in-
sulin before dinner). The six remaining
patients were treated with two daily injec-
tions (30% regular/70% NPH insulin).
After determination of VO2max, patients
reported to the laboratory on two separate
occasions, 1 week apart, in randomized
order 90 min after breakfast (60 g carbo-
hydrates, 10 g lipids, and 8 g proteins) to
perform a 60-min exercise session on an
ergocycle at 70% VO2max. On one occa-
sion, exercise was performed with the
usual morning insulin dose. On the other,
morning insulin dose was reduced by
90% for patients treated with three daily
injections and by 50% for patients treated
with two injections per day. Power output
was monitored and strictly maintained
during the tests to correspond to 	70%
VO2max.
Changes in plasma glucose (PG) lev-
els were analyzed by a mixed-model AN-
COVA, with a random subject effect and
random coefficients for time within each
subject, using the SAS version 6.12 soft-
ware package (SAS Institute, Cary, NC).
At the beginning of exercise and over
the test period, PG levels were higher in
the experimental condition with insulin
dose reduction (P  0.0001) (Fig. 1).
Changes in PG levels were similar in both
conditions during exercise and recovery
(P  0.99). No difference was observed
when considering insulin regimen. Dur-
ing exercise, the mean decrease in PG
concentrations was 0.085  0.012
mmol  l1  min1 (mean  SE) (P 
0.0001), whereas no significant variation
was observed during the recovery period.
When exercise was performed without re-
ducing insulin doses, eight patients
(66%) had hypoglycemia and were given
oral sucrose (22  3 g). Changes in
plasma lactate, growth hormone, cortisol,
glucagon, and norepinephrine were not
statistically different. The peak of plasma
epinephrine concentration was higher in
the test without insulin reduction: 2.3 
1.5 vs. 1.1  0.7 nmol/l (P  0.04, Stu-
dent’s t test).
In previous studies, decreasing insu-
lin dose before moderate exercise (	55%
VO2max) was not associated with degrada-
tion in blood glucose control during and
after exercise (1,4,5). However, most
sport activities, whether individual (run-
ning, biking, hiking, and swimming) or
team (basketball, football, and handball)
involve intense muscle exercise. We show
here that a 90% reduction of morning reg-
ular insulin before intense exercise allows
the maintenance of near normal blood
glucose levels without occurrence of hy-
poglycemia. When insulin was not re-
duced, two-thirds of patients experienced
hypoglycemia.
This study emphasizes the impor-
tance of insulin-independent contrac-
tion-induced glucose uptake by muscle,
previously demonstrated in healthy men
(6) and mice lacking muscle insulin re-
ceptor (rev. in 7).
In conclusion, we demonstrate that
type 1 diabetic patients can perform in-
tense muscle exercise after a 50–90% re-
duction in insulin dose, depending on
their insulin regimen. This decrease pre-
vents hypoglycemia without worsening
metabolic control. Such advice could be
given to young type 1 diabetic patients
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Figure 1—Changes in PG levels during
exercise and recovery performed with
(f) and without () insulin reduction.
Of 12 patients, 8 received oral glucose
during the condition without insulin re-
duction. Data are expressed as mean 
SE (n  12).
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In 1997, we reported the first identifiedcase of mitochondrial diabetes causedby a T-to-C transition at position 3264
(1). The patient had type 2 diabetes, li-
poma, facial palsy, ophthalmoplegia, and
hearing loss. His unique profile suggests
the heterogeneity of mitochondrial
(mt)DNA-related diabetes. Among the
characteristics, bilateral facial palsy and
ophthalmoplegia (right eye) were note-
worthy because they have not been
reported in mitochondrial diabetes asso-
ciated with other pathogenetic mutations.
At age 59 years, facial palsy appeared first
on the right side and 6 months later on the
left side. It occurred without pain and be-
came persistent. At age 64 years, ophthal-
moplegia occurred with transient ocular
pain with ptosis and pupillary sparing. In-
terestingly, during the follow-up we ob-
served that serum acetylcholine receptor
antibody was positive at age 65 years (0.6
nmol/l; the titer is considered to be positive
at 0.2 nmol/l, which is 2 SD above the
mean of 170 normal control subjects).
Edrophonium chloride (Tensilon) test was
negative. Repetitive nerve stimulation was
negative, and GAD antibody was negative.
Disordered autoimmunity such as is-
let cell antibody (ICA) and GAD antibody
has been described in several case reports
of mitochondrial diabetes or MELAS (mi-
tochondrial encephalopathy, lactic acido-
sis, and stroke-like episodes) (2–4). As
for acetylcholine receptor antibody, it has
been reported in two elderly women with
external ophthalmoplegia; one of the two
women had diabetes (5). Because ragged-
red fibers and elevated lactic acid were
observed in the patients, Mitsikostas et al.
pointed out that ophthalmoplegia and
acetylcholine receptor antibody are corre-
lated with mitochondrial myopathies.
Therefore, in this case, the association of
cranial nerve palsies and positive acetyl-
choline receptor antibody may not be a
fortuitous coincidence. It was speculated
that mitochondrial DNA abnormality
causes not only diabetes but also the
immune destruction associated with ace-
tylcholine receptor antibody, which de-
velops bilateral facial nerve palsy and
ophthalmoplegia.
However, as for ophthalmoplegia,
this patient’s condition was complicated
with ocular pain at onset and did not re-
spond to the tensilon test. Because pain is
not a manifestation of myasthenia gravis,
vascular factors may be involved, overlap-
ping on the pathogenesis of autoimmune
factor. Since the report of Asbury et al. (6)
in 1970, the etiology to understand oph-
thalmoplegia in diabetes has been
hypothesized to result from diabetic mi-
crovascular injury involving small vessels
that supply nerves. This patient had
strongly succinate dehydrogenase reac-
tive vessels that contained proliferation of
abnormal mitochondria in the smooth
muscle cells (1). Therefore, the ophthal-
moplegia might be triggered by vascular
events associated with a proliferation of
abnormal mitochondria in vascular
smooth muscle cells. Thus, this case sug-
gests that cranial mononeuropathies in
diabetes could possibly be caused by the
synergistic effects of mitochondrial ge-
netic abnormality, disordered autoimmu-
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The U.K. National Screening Com-mittee recommended digital fundusphotography as the screening
method of choice for diabetic retinopathy
(DR). However, concerns have been ex-
pressed about replacing ophthalmoscopy
with slit-lamp biomicroscopy by digital
photography. These concerns included
the possibility of missing peripheral and
stereoscopic visible retinal lesions; in-
creased chance of a technical failure com-
pared with ophthalmoscopy, resulting in
more reexaminations; and higher cost (1).
New data from our study of 453 patients
with diabetes, aged 31–86 years, high-
light the need for a careful consideration
of the retinal area photographed and the
minimal resolution of images to detect DR.
We compared nonstereoscopic two-
field 45o digital fundus photography after
pharmacological mydriasis with indirect
ophthalmoscopy and slit-lamp biomi-
croscopy performed by an ophthalmo-
logically trained physician for the
Letters
1318 DIABETES CARE, VOLUME 26, NUMBER 4, APRIL 2003
detection of any DR. The photographs
were made with a Canon CR5 nonmydri-
atic camera, interfaced to a 3-CCD color
video camera (resolution 785 576 pix-
els). They were digitized, compressed
(10:1 JPEG), and independently analyzed
by the ophthalmologically trained physi-
cian and an ophthalmologist with a 17-
inch monitor using Adobe Photoshop. In
cases of disagreement, the judgement of
another ophthalmologist was decisive.
DR was detected by ophthalmoscopy in
16% of 442 right eyes that had both oph-
thalmoscopy and any gradable photogra-
phy, as well as by photography in 8%. The
agreement was moderate ( statistic
0.54  0.06) due to a sensitivity for de-
tection of DR by photography of 44%
compared with ophthalmoscopy. One
reason for this low sensitivity could be
that the resolution of the digital photo-
graphs was too low to detect small retinal
lesions; 68% of the eyes with retinopathy
missed by digital photography had only
microaneurysms, small dot hemorrhages,
or hard exudates in the area of both pho-
tographic fields. This is expected to
become less of a problem because digi-
tal resolution improves rapidly in new
cameras. However, the other reason for
the low sensitivity of fundus photography
was that retinal lesions were located out-
side the two photographic fields in 17%
of the eyes with DR discovered by
ophthalmoscopy.
This study focused on comparison of
detecting any DR, since, except for two
eyes treated with photocoagulation, only
eyes with minimal and moderate nonpro-
liferative retinopathy were detected. The
U.K. Prospective Diabetes Study showed
that microaneurysms alone are predictive
for worsening retinopathy after 3–12
years (2). Therefore, it may be important
to also detect small lesions, since these
may be the first signs that blood glucose
or blood pressure control needs to be re-
evaluated or possibly intensified. Further-
more, detection of any retinopathy
instead of no retinopathy might indicate
other reexamination intervals, while less
sensitive detection methods could give
patients false reassurance that their mi-
crovascular status is in good condition.
HENDRIK A. VAN LEIDEN, MD1,2
ANNETTE C. MOLL, MD, PHD1,2
JACQUELINE M. DEKKER, PHD2
MICHAEL D. ABRAMOFF, MD, PHD1,3
BETTINE C.P. POLAK, MD, PHD1,2
From the 1Department of Ophthalmology, VU Uni-
versity Medical Center, Amsterdam, the Nether-
lands; the 2Institute for Research in Extramural
Medicine, VU University Medical Center, Amster-
dam, the Netherlands; and the 3Image Sciences In-
stitute, Utrecht Medical Center, Utrecht, the
Netherlands.
Address correspondence to Hendrik A. van Lei-
den, MD, VU University Medical Center, Depart-
ment of Ophthalmology, P.O. BOX 7057, 1007 MB
Amsterdam, The Netherlands. E-mail: ha.vanleiden
@vumc.nl.
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
References
1. Prasad S, Swindlehurst H, Cleaqrkin LG:
National screening programme for dia-
betic retinopathy: screening by optome-
trists is better than screening by fundus
photography. BMJ 323:998–999, 2001
2. Kohner EM, Stratton IM, Aldington SJ,
Turner RC, Matthews DR: Microaneu-
rysms in the development of diabetic ret-
inopathy (UKPDS 42): U.K. Prospective
Diabetes Study Group. Diabetologia 42:
1107–1112, 1999
Health-Related




H aving type 1 diabetes will perma-nently change a patient’s life. Fromthe moment of diagnosis, patients
will have to consider their diet, insulin
therapy, exercise, and self-monitoring of
blood glucose every day. This will influ-
ence a patient’s health-related quality of
life (1).
The aim of this study was to investigate
the health-related quality of life of patients
with newly diagnosed type 1 diabetes in
the first year after diagnosis and to com-
pare their health-related quality of life, 1
year after diagnosis, with people of com-
parable age from the general population.
Health-related quality of life was as-
sessed using the RAND-36 (2). The
RAND-36 is an instrument containing
eight different life domains, from which a
physical component summary (PCS) and
a mental component summary (MCS) can
be calculated. Wilcoxon’s signed-rank
tests were used to compare scores at base-
line with scores at 1 year and to compare
scores between populations.
We studied 15 patients (5 men and
10 women) with newly diagnosed type 1
diabetes aged 29.2  12.0 years (range
14–54; mean  SD). HbA1c levels de-
clined significantly after 1 year (14.3 vs.
6.9%, P  0.001).
The PCS showed a statistically signif-
icant improvement in the first year after
diagnosis from 48.8  7.3 to 54.4  3.4
(P  0.004). The MCS increased but did
not show a statistically significant in-
crease 1 year after diagnosis (47.1 12.5
to 50.8  11.5, P  0.173).
After 1 year, health-related quality of
life was comparable with that of subjects
in the general population (PCS 52.8 
1.8, P  0.053; MCS 50.7  1.5, P 
0.570).
Although health-related quality of life
is initially decreased when the diagnosis
of type 1 diabetes is made, the impact of
all the cumbersome aspects of the disease
appears to be minimal 1 year after diag-
nosis. Therapy and self-management are
apparently accepted and incorporated
fairly quickly into daily life, at least in the
first year after diagnosis. Although the
number of patients included in this study
is not large, we nevertheless found statis-
tically significant changes in health-
related quality of life over time.
We can conclude that health-related
quality of life, physical health-related
quality of life in particular, improves in
patients with newly diagnosed type 1 di-
abetes within the first year after diagnosis.
One year after diagnosis, health-related
quality of life is comparable with that of
subjects from the general population.
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Subjects With Type 1
Diabetes
G lomerular filtration rate (GFR) isconsidered the best marker of renalfunction, and its estimation using
inulin or 51Cr-EDTA is considered the
“gold standard.” Such determination is in-
convenient and often replaced by an esti-
mate of creatinine clearance (CrCl)
derived from the formula of Cockroft and
Gault (CG). Serum cystatin-C was re-
cently proposed as a reliable alternative
routine marker of GFR in pediatric, adult,
and elderly subjects (1– 4). Although
Dharnidharka et al. (5) thouroughly re-
view the issue of comparing cystatin-C
and creatinine in relation to reference
GFR measurements, few reports deal with
the comparison of serum creatinine and
cystatin-C in diabetic patients (5–9).
Odozze et al. (6) suggested that serum
cystatin was not superior to creatinine for
estimating GFR in type 1 and type 2 dia-
betic patients with early renal impair-
ment, while others clearly hint toward
cystatin-C measurement being a more
sensitive and specific GFR marker in type
2 diabetic subjects with normal or slightly
reduced GFRs (5–8). Mussap et al. (9)
found that cystatin-C was more accurate
than creatinine in discriminating diabetic
subjects according to 51Cr-EDTA GFR.
In the November 2002 issue of Dia-
betes Care, Tan et al. (10) reported the
clinical usefulness of cystatin-C for GFR
estimation in subjects with type 1 diabe-
tes using iohexol clearance as the “gold
standard” GFR measurement and dis-
criminant ratio (DR) methodology (10,
11). Using the same DR approach (11),
we assessed, from intra- and intersubject
variability, the performance of cystatin-C
(particle-enhanced immunonephelomet-
ric method, N Latex Cystatin-C; Dade Be-
hring) in 46 subjects with type 1 diabetes
spanning a wide range of kidney function,
as compared with that of serum creatinine
(8). Age and diabetes duration were 45
16 and 18  12 years, respectively, BMI
24  3 kg/m2, and HbA1c 8.7  1.5%.
Median CrCl estimated by the CG for-
mula was 92 ml/min (range: 15–149; 25–
75th percentile: 81–110), adjusted to a
body surface area of 1.73 m2, with
normo- (CG 70 –120 ml/min), hyper-
(CG120), and hypofiltration (CG70)
present in 63, 20, and 17%, respectively.
Serum creatinine levels were 1.01 0.73
and 1.02  1.00 mg/dl and cystatin-C
1.00  0.67 and 0.98  0.73 mg/l on
days 1 and 2, respectively. A close linear
relationship was observed between means
of duplicates for creatinine and cystatin-C
(Pearson product-moment correlation
0.97). The DR (ratio of the underlying
between-subject to within-subject SD)
was 3.92 for creatinine and 9.09 for cys-
tatin-C (P  0.0001), implying superior
discriminating ability for cystatin-C.
Once adjusted for attenuation, measured
Pearson product-moment correlation in-
creased to 1.00. The unbiased linear re-
gression equation between methods had
a slope of 0.83 and an intercept at 0.16.
We conclude that serum cystatin-C better
discriminates among a population of type
1 diabetic patients with regard to their
estimated GFR, as compared with con-
ventional serum creatinine measurement,
and recommend its routine use for esti-
mating kidney function in this population.
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D iabetes Control and ComplicationsTrial results showed that strict met-abolic control may substantially re-
duce the risk of long-term microvascular
complications (1). Over the study period,
which averaged 7 years, the mean HbA1c
level in the intensive group treatment was
7.2%. Current guidelines of treatment for
type 1 diabetes propose a goal of HbA1c
7% (2). Nevertheless, in usual clinical
practice, an acceptable metabolic control
is achieved in a too low proportion of pa-
tients, even under multiple daily insulin
injections (MDIs) (3). A recent meta-
analysis of randomized trials concluded
that continuous subcutaneous insulin in-
fusion (CSII) permits a small improve-
ment in blood glucose control with
respect to MDIs (4). Glargine insulin is a
human insulin analog that might mimic
the effects of CSII at single basal infusion
rate. Preliminary studies indicate that
glargine may reduce the incidence of hy-
poglycemia and fasting blood glucose
compared with NPH (5).
Whether an MDI treatment with glar-
gine as long-acting insulin may offer sim-
ilar results to those obtained with CSII is
still unknown (6). For this purpose, we
evaluated, in an open parallel group trial
of 1-year duration involving 32 type 1 di-
abetic patients that had been treated with
MDIs (regular or lispro insulin before
each meal plus NPH as basal insulin) for
at least 1 year, the efficacy of two regimens
of intensive insulin treatment: CSII versus
MDIs with lispro at each meal plus glar-
gine as basal insulin. These patients were
selected because of poor metabolic con-
trol (HbA1c 8% in the previous year)
despite MDI treatment. Two patients in
both groups had a history of severe hypo-
glycemic episodes. Data are expressed as
mean  SD.
Sixteen type 1 diabetic patients (age
37.7 11.2 years, 8 men, 8 women, du-
ration of diabetes 19.6  9.2 years) were
treated with CSII, receiving lispro at mul-
tiple basal infusion rates plus boluses at
meals, for a 1-year period (CSII group).
Sixteen type 1 diabetic patients (age
42.9 15.6 years, 7 men, 9 women, du-
ration of diabetes 14.7 11.1 year) were
treated with MDIs with lispro at each meal
combined with glargine injected at dinner
or at bedtime, for a 1-year period (glargine
group).
In all patients, HbA1c, fasting blood
glucose, total cholesterol, HDL choles-
terol, triglycerides, uric acid, insulin re-
quirement, and severe hypoglycemic
episodes (i.e., hypoglycemic event requir-
ing assistance from another person or re-
sulting in a seizure or coma) were
evaluated every 3 months during the year
before the study and during active treat-
ment. We compared the mean  SD of
these parameters for the year preceding
the study with those of active treatment
(CSII or glargine) using the Student’s t test
for paired data.
In the CSII group, compared with tra-
ditional MDI treatment, there was a sig-
nificant decrease of HbA1c (9.2  1.6%
during traditional MDI vs. 8.2  1.2%
during CSII, P  0.001), fasting plasma
glucose (11.9 3.5 vs. 8.1 2.8 mmol/l,
P  0.001), triglycerides (100.9  41.6
vs. 85.5  41.4 mg/dl, P  0.05), severe
hypoglycemic episodes (0.37 vs. 0.12 per
patient/year, P  0.05), and insulin re-
quirement (50.4  18 vs. 40.1  13.1
units/day, P  0.001). In the glargine
group, compared with traditional MDI
treatment, there was a significant decrease
of HbA1c (8.5 1.3 vs. 7.9 1.2%, P
0.001), fasting plasma glucose (12.3 
3.9 vs. 10.5  3.1 mmol/l, P  0.001),
triglycerides (90.6 50.8 vs. 77.0 39.3
mg/dl, P  0.05), and severe hypoglyce-
mic episodes (0.43 vs. 0.18 episodes per
patient/year, P  0.05). Insulin dose was
unmodified (44.0 11.1 vs. 43.1 11.1
units/day, NS). There was no significant
change in BMI in either the CSII (24.7 
4.2 vs. 24.6 4 kg/m2) or glargine group
(22.8  2.9 vs. 22.9  3 kg/m2).
We compared the responses to CSII
and MDI with glargine by analyzing (us-
ing a nonpaired t test) the differences be-
tween measured variables before and after
the two treatments. No significant differ-
ence between the two groups was present
in the degree of improvement of HbA1c,
fasting plasma glucose, triglycerides, or
severe hypoglycemic episodes. Only insu-
lin requirement reduction was signifi-
cantly greater in the CSII than in the
glargine group (10.3 3.3 vs.0.9
0.3 units/day, respectively, P  0.001).
The number of severe hypoglycemic
episodes decreased both during pump
treatment and during lispro plus glargine
treatment, confirming the results of pre-
vious controlled trials (4). These findings
are probably related to the lower variabil-
ity in subcutaneous insulin absorption
during CSII and to the unique profile of
glargine biological action (5).
In our study, CSII was not associated
with an increase in body weight. The pres-
ence of a dietitian specifically dedicated to
this patient group may have helped to
avoid this adverse effect of CSII (7).
In conclusion, we demonstrated that
both CSII and MDIs with lispro plus
glargine equally improve metabolic con-
trol and reduce severe hypoglycemia in
type 1 diabetic patients that are unsatis-
factorily controlled on MDIs using NPH
as basal insulin.
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Continuous subcutaneous insulin in-fusion (CSII) is believed to moreclosely mimic pancreatic function
and therefore to create more stability in
blood glucose than multiple daily insulin
injections (MDIs). One of the unique fea-
tures of CSII is the ability to preprogram
changes in basal insulin delivery. This fea-
ture is especially useful during the night
when insulin pharmacokinetics and the
dawn phenomenon may change basal in-
sulin requirements (1). Glargine is an
insulin analog designed to mimic endog-
enous insulin secretion patterns and has
been proposed as a longer-acting, peak-
less insulin that can be administered once
a day, usually at bedtime (2). In the
present study, glargine was compared,
during nighttime hours, with prepro-
grammed rates of lispro delivery in pa-
tients using CSII.
A sample of 19 patients, already
scheduled for continuous glucose moni-
toring system (CGMS; Medtronic Mini-
Med, Northridge, CA) evaluation, were
included in the study. CGMS data were
compared between 11 subjects on CSII
(lispro) and 8 subjects on MDIs (lipro and
glargine) and were evaluated during the
overnight period. Age (46.4  10.5 vs.
40.4  10.0 years), duration of diabetes
(9.6  5.3 vs. 15.5  8.7 years), and
HbA1c (7.3  0.6 vs. 7.1  1.0%) were
similar between the groups.
Significant differences in nighttime
glucose control were identified as a func-
tion of type of therapy. Subjects treated
with glargine spent significantly more
time outside target sensor glucose ranges
(70 –200 mg/dl) than subjects treated
with CSII (50.7 vs. 20.9%, P  0.04).
Specifically, subjects treated with glargine
experienced a threefold increase in time
exposed to glucose values 70 mg/dl
when compared with subjects treated
with CSII (34.7 vs. 12.8%, P  0.03).
Subjects treated with glargine spent twice
the amount of time exposed to glucose
values 200 mg/dl (16.0 vs. 8.1%, P 
NS). The average hourly basal insulin rate
was significantly greater in subjects
treated with glargine than subjects treated
with CSII (0.8 0.4 vs. 0.5 0.3 units 
kg1  h1, P  0.002). The mean num-
ber of nocturnal basal rate settings used
by the CSII group was 2.4 0.7; changes
in basal rate are not possible with
glargine.
These results highlight the challenges
in developing a basal insulin that works as
effectively as CSII therapy. Statistically
equivalent baseline HbA1c between the
two groups reflected a balance between
the time spent with glucose values 200
mg/dl and 70 mg/dl in the glargine
group and time spent within target sensor
glucose values in the CSII group. Lepore
et al. (3) report that “an ideal basal insulin
candidate is a peakless, long-lasting prep-
aration that mimics the flat interprandial
insulin secretion of nondiabetic subjects,
with reproducible subcutaneous absorp-
tion.” According to the ideal basal insulin
requirements suggested by Lepore et al.,
glargine appears to be superior to other
intermittent, or long-acting, insulins such
as NPH, lente, and ultralente. However,
our results suggest that while glargine
may most closely meet the criteria set by
Lepore et al., the ideal basal insulin must
also be delivered at a variable rate to sat-
isfy changing daily insulin requirements.
CSII is the only current means of achiev-
ing this variable rate.
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Case report and review of literature
A 70-year-old patient with refractorymultiple myeloma, renal failure,and colon cancer was admitted with
severe hyperglycemia (612 mg/dl). Dur-
ing the previous 3 weeks he had devel-
oped polyuria, polydipsia, fatigue, and a
2-kg weight loss. He had no personal or
family history of diabetes. He had devel-
oped stress-related hyperglycemia during
hospitalization for colon cancer surgery 4
years earlier. He was treated with insulin
in the hospital and discharged on medical
nutrition therapy. He was diagnosed with
multiple myeloma 3 months later and was
treated with chemotherapy and steroids
for 12 months. His plasma glucose levels
ranged from 98 to 114 mg/dl during this
period. He was not treated with glucocor-
ticoids or antidiabetic agents for the next
3 years, and during this period plasma
glucose values were 125 mg/dl. Four
weeks prior to this hospitalization, thalid-
omide 400 mg/day was started for treat-
ment of refractory multiple myeloma.
Physical examination revealed an afebrile
thin patient (BMI 21 kg/m2), and no pre-
cipitating factors for diabetic ketoacidosis
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were identified. Laboratory investigations
showed no acidosis, ketonuria, or leuko-
cytosis. A1C was elevated at 9.9%. He re-
ceived 10 units of regular insulin
subcutaneously on admission. His subse-
quent capillary blood glucose values
(with corresponding insulin doses in pa-
rentheses) were 512 (10 units), 247 (2
units), 282 (4 units), 126 (0 units), and
94 mg/dl (0 units). He received a total of
26 units of regular insulin over a period of
36 h. He refused insulin therapy on a
long-term basis and was treated with
glipizide GITS 5 mg/day. Three weeks
later his symptoms were resolved. His
fasting plasma glucose values 4, 8, 12, and
16 weeks after admission were 83, 151,
141, and 80 mg/dl, respectively. A1C af-
ter 20 weeks of glipizide GITS therapy
was 5.4%. Thalidomide therapy was con-
tinued for treatment of his myeloma.
Thalidomide, withdrawn for terato-
genicity, was reintroduced in 1997 as an
immunomodulator to treat erythema no-
dosum leprosum. Its mechanism of action
is thought to involve the inhibition of tu-
mor necrosis factor (TNF)-–mediated
angiogenesis of the lesion. To our knowl-
edge, thalidomide treatment has not pre-
viously been reported to cause or to
worsen diabetes. We believe this to be the
first report of extreme hyperglycemia oc-
curring after initiation of thalidomide
therapy. Iqbal et al. (1) investigated the
role of thalidomide as a TNF- antagonist
on six patients with diabetes. They ad-
ministered placebo or 150 mg of thalido-
mide for 3 weeks in a crossover design
and performed isoglycemic-hyperinsu-
linemic clamps before and after therapy.
They reported that thalidomide decreased
insulin-stimulated peripheral glucose up-
take by 31% (increased insulin resistance)
and decreased glycogen synthesis by
48%. Wilson et al. (2) studied insulin an-
tagonism by using a bioassay (rat dia-
phragm assay) in mothers giving birth to
children with congenital malformations
in 1966. They observed that antagonism
to insulin was present in 5 of 6 (83%)
mothers exposed to thalidomide in their
first trimester compared with 14 of 50
(28%) mothers in the control group.
In a prostate cancer study, Figg et al.
(3) observed that decreasing the dose of
thalidomide improved hyperglycemia,
suggesting that thalidomide may have
contributed to the hyperglycemia. Our
patient developed diabetes shortly after
initiation of thalidomide. We believe this
to be the first report of extreme hypergly-
cemia associated with thalidomide therapy.
This case should prompt additional
studies to evaluate hyperglycemia in pa-
tients treated with thalidomide. Until
then, we recommend screening for diabe-
tes before thalidomide treatment and reg-
ular follow-up of plasma glucose levels.
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The pattern and degree of myocardialinvolvement in maternally inheriteddiabetes and deafness (MIDD) is un-
clear (1–3). A recent French multicenter
study that examined 54 patients with
MIDD described left ventricular hypertro-
phy (LVH) in 8 and congestive heart fail-
ure (CHF) in 2 patients (2). Here, we
reported a patient with mtDNA 3243 mu-
tation who developed the full clinical,
echocardiographic, and radiologic pic-
ture of CHF.
A 54-year-old man with diabetes
since age 23 years was diagnosed as hav-
ing MIDD based on the findings of deaf-
ness, familial history of diabetes, and
short stature involving his younger brother
and mother. His older brother also pre-
sented diabetes but not short stature or
deafness. Insulin was started when the pa-
tient was age 38 years, and he never pre-
sented ketosis. On physical examination,
blood pressure was normal. Right hemi-
paresy was present as sequelae of a previ-
ous cerebrovascular accident. Autonomic
and peripheral neuropathy were de-
tected. Fundoscopy disclosed nonprolif-
erative diabetic retinopathy. Laboratorial
evaluation included a glucagon test that
displayed decreased pancreatic insulin se-
cretion (baseline and 6-min C-peptide
values of 1.2 and 1.3 ng/ml, respectively).
Urinary albumin excretion was 1,112
mg/24 h, and serum creatinine was 1.6
mg/dl. The younger brother and mother,
but not the older brother, also presented
macroalbuminuria. The analysis of mito-
chondrial DNA obtained from peripheral
leukocytes revealed an A3G mutation at
position 3243 in the patient and in his
mother. The older and younger brother
were not affected. Cerebral MRI revealed
multiple hyperintense areas in cortex,
globus pallidus, and cortical atrophy.
Blood lactate concentration was 1.45
mmol/l at baseline (n  0.3–1.3 mmol/l)
and increased to 2.26 mmol/l after a
carbohydrate-rich meal. Thyroid hor-
mone concentrations were T4  2.6
g/dl (normal range 4.5–12.5 g/dl),
thyroid-stimulating hormone  16.4
UI/ml (upper limit 4.5 UI/ml). Anti-
thyroperoxidase was normal, and oral
thyroxine was started. An echocardio-
gram was performed and revealed a dif-
fuse pattern of birefringence, which is
suggestive of myocardial infiltration with
an ejection fraction of 54% and LVH. The
blood cell count found 20,000 leuko-
cytes, with 34% of eosinophils. The pa-
tient’s records confirmed eosinophilia
(exceeding 1,500/l) in the previous 6
months, which persisted after antipara-
sitic treatment. The presumptive diagno-
sis of eosinophilic myocardial dysfunc-
tion was assumed and prednisone therapy
(60 mg/day) was started.
The patient visited the emergency
unit 4 months later presenting resting
dyspnea and pronounced bilateral lower-
limb edema. A chest X-ray revealed the
presence of pulmonary effusion. The elec-
trocardiogram showed possible lateral
ischemia and atrial enlargement. The
echocardiogram disclosed a small peri-
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cardial effusion, a diffuse birefringence
pattern, and an ejection fraction of 41%,
suggesting myocardiopathy. Cardiac
catheterization was performed and re-
vealed a 50% segmental lesion on the an-
terior descendent artery. A myocardial
biopsy was indicated and demonstrated
muscle fiber hypertrophy and degenera-
tive changes, features consistent with the
presence of dilated cardiomyopathy,
eliminating the diagnosis of eosinophilic
myocardiopathy.
Previous cases of cardiac dysfunction
in mitochondrial diabetes have been de-
scribed (2–4). A Japanese group showed
the fast progressive nature of cardiac in-
volvement in a diabetic patient who de-
veloped mitochondrial cardiomyopathy,
with diffuse left ventricle hypokinesis.
The endomyocardial biopsy described
mild hypertrophy and myofibrils disar-
rangement with vacuolar degeneration, a
pattern similar to our findings. Accord-
ingly, our patient also presented a fast
progression to heart failure, with deterio-
ration of cardiac function over a period of
4 months. Momiyama et al. (5) studied 12
diabetic patients with mtDNA 3243 mu-
tation and pointed out that they have a
significantly higher proportion of LVH as
compared with ordinary diabetic patients
(33 vs. 7%). We believe that the present
report contributes to characterize the
myocardial involvement in the mitochon-
drial syndrome, providing clues to under-
standing the related disease mechanisms.
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Smoking has been pinpointed as afactor causing progression of chronicnephropathies. It is worth noting
that smoking increases urinary albumin
concentration, even at albumin concen-
trations below that of microalbuminuria
(1). There is growing evidence that smok-
ing not only increases the risk of albumin-
uria but also the risk of renal functional
deterioration. The frequency of nephrop-
athy is progressively higher with increas-
ing cigarette consumption. The available
literature documents that smoking in-
creases the risk of developing micro-
albuminuria, accelerates the rate of pro-
gression from microalbumunuria to man-
ifest proteinuria, and accelerates the
progression of renal failure (1). Chase et
al. (2) reported that in a group of 359
young patients with type 1 diabetes, the
prevalence of borderline and frankly ele-
vated urinary albumin excretion rates was
2.8-fold higher in smokers than in non-
smokers. Concerning the risk of mi-
croalbumunuria progressing to overt
proteinuria, a 4-year prospective study on
794 patients with type 2 diabetes reported
a 2- to 2.5-fold higher relative risk in
heavy smokers than in nonsmokers (3).
Cigarette smoking in patients with kidney
disease, including diabetic nephropathy,
is associated with myointimal hyperplasia
of intrarenal arteries, and there is a trend
toward arteriolar hyalinosis in smokers.
The renal vessels are the main targets of
cigarette smoke in the kidney (4). In ad-
dition, smoke damages endothelial cells,
and nicotine induces smooth muscle cell
proliferation (5). However, the effects of
smoking on podocyte injuries in patients
with diabetic nephropathy are still unclear.
The podocyte is a highly differenti-
ated cell that is strategically located on
the outside of the glomerular capillary
wall. Podocytes play an important role in
glomerular filtration. Injuries to the podo-
cytes are accompanied by marked mor-
phological changes. The most severe
podocyte lesion occurs as podocytes de-
tach from the glomerular basement mem-
brane, and these cells subsequently
appear in the urine (6). By measuring uri-
nary podocytes, we previously reported
that podocyte injury may occur in pa-
tients with early diabetic nephropathy
(7). Meyer et al. (8) reported that among
the glomerular morphological character-
istics used to diagnose nephropathy, uri-
nary podocyte number was the best
predictor in diabetic patients. The aim of
the present study was to determine
whether smoking affects podocyte inju-
ries in patients with type 2 diabetes with
microalbuminuria.
Eighty type 2 diabetic patients with
microalbuminuria (50 men and 30
women, mean age 50.8 years, 50 smokers
and 30 nonsmokers) and 30 healthy sub-
jects (18 men and 12 women, mean age
49.5 years) were included in the present
study. No patients had serum creatinine
levels in excess of 2.0 mg/dl. Urinary
podocytes were examined by immunoflu-
orescence microscopy as previously re-
ported (6,7). Urinary podocytes were
detected in 35 diabetic patients with mi-
croalbuminuria (27 smokers and 8 non-
smokers, 1.4 0.7 cells/ml) but were not
detected in the remaining 45 patients (23
smokers and 22 nonsmokers) or the 30
healthy subjects. More podocytes are ex-
creted in the urine in smokers (27 of 50
patients) with microalbuminuria than in
Letters
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nonsmokers (8 of 30 patients) with mi-
croalbuminuria (P  0.017, 2 test). The
27 diabetic patients (smokers) who had
urinary podocytes were divided into two
groups: 13 patients who stopped smok-
ing and 14 patients who continued smok-
ing. Urinary podocytes disappeared after
3 years in 10 of the 13 patients who had
stopped smoking, whereas urinary podo-
cytes increased in all patients who contin-
ued to smoke (from 1.1  0.8 to 1.7 
0.4 cells/ml, P  0.01). These data sug-
gest that smoking may be associated with
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The influence of worldview and the
difficulty of overcoming our
training
In reading the recent report by Kirkmanet al. (1), I was simultaneously im-pressed and troubled. I was impressed
by the attempt of this important work to
improve the quality of care among seven
rural primary care practices. Their de-
tailed reporting of both initial and long-
term results, and of both quality of care
and physiological outcomes, was impres-
sive. Especially noteworthy was their in-
clusion of longer-term, 2-year data,
which are seldom reported. Their candor
in discussing the failure to maintain the
initial performance improvements, as
well as their insightful discussion of po-
tential reasons for these findings and the
characteristics of systems that success-
fully improve quality, are refreshing and
informative.
I was troubled, however, by the find-
ings concerning the smoking cessation
counseling index. I was struck by the va-
lidity of the observations of Kuhn (2) and
Anderson (3), especially pertaining to di-
abetes management, that one’s worldview
determines how problems are identified
and addressed. The authors report that
they dropped any further consideration of
improvement on the smoking cessation
measure due to the very low baseline level
of documentation of smoking status. I
wonder, if this had been the case with low
levels of documentation of A1C status,
would the authors have made a similar
decision? Instead, they would likely have
used this as a rationale for redoubling
their efforts to regularly collect and inter-
vene on this measure. The dropping of
smoking documentation and counseling
was especially disappointing given the
unquestioned clinical importance of
smoking status and the availability of very
cost-effective primary care–based inter-
ventions to improve smoking assessment
and counseling (4).
I cannot help but speculate whether
the prevailing biomedical perspective in
which many of us have been trained (and
which still largely dominates diabetes care
[3]) did not influence this decision. An-
other finding reported in the Kirkman et
al. (1) article further heightened this im-
pression: the patient education program
did not impact many of the intended pa-
tients in these practices. It would seem to
be a well-integrated clinical activity to
have a patient education program that
was tied to the quality issues that the pro-
viders were focusing on. However, there
are two major concerns: 1) the decision to
offer group-based educational sessions on
a predetermined topic, rather than prob-
lem-based learning and self-management
sessions on topics of interest and concern
to patients (5,6), and 2) most diabetes ed-
ucators have been trained to offer such
group sessions and continue to do so, de-
spite strong evidence that even under the
best conditions, only a minority of pa-
tients will attend such sessions, and this
modality often fails to reach those who are
most in need of such assistance. If instead
an approach had been used that focused
on the ultimate panel or population-
based impact (7) (e.g., www.re-aim.org),
and on problem-based learning that was
focused on issues of concern to patients, it
is likely that alternative approaches, such
as nurse-based self-management training
or proactive phone counseling, would
have been selected.
My purpose is not to criticize these
investigators, who are leaders in their
field and have provided an important re-
port that focuses on many of the complex
issues involved in translating research
into practice. Rather, the point is that we
all need to “think differently” and to ask
hard questions of ourselves when faced
with such translation challenges. The
models and methods in which most of us
have been trained have been partial
causes of our current dilemma. As Ein-
stein is reported to have said, “The signif-
icant problems we face cannot be resolved
by thinking at the same level that created
the problems.”
It is hoped that evidence-based
guidelines that place equal emphasis on
important patient self-management be-
haviors as on laboratory assays and check-
lists and flow diagrams, such as those
being developed by the Evidence-Based
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Behavioral Medicine Committee of the
Society of Behavioral Medicine (8), will
help us to think differently, to ask the
hard translation questions, and to exper-
iment with the innovations necessary to
close the quality chasm.
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W e appreciate Dr. Glasgow’s (1)interest in our article (2) and theopportunity to respond to his
comments. He seems to impute a biased
worldview to our decision to drop smok-
ing cessation counseling from chart audits
subsequent to the baseline audit. First, we
can assure him that we were not disinter-
ested in the issue of smoking, as evi-
denced by the fact that this was one of the
areas identified up front as important by
the primary care physicians who invited
us into their community. Data collection
limitations alone drove the decision to
drop this measure from subsequent anal-
yses. Our sole source of data for the study
was the charts kept by a group of inde-
pendent solo practitioners, each of whom
had a different system for keeping patient
information. The auditors had to extract a
wealth of information about both physi-
cian and patient behavior from these
charts in a highly labor-intensive process.
For each measure of adherence to guide-
lines, we had to ascertain both a numera-
tor (the number of patients whose charts
showed that they received the recom-
mended care) and a denominator (the
number of eligible patients). In all guide-
line areas except smoking cessation coun-
seling, including the example Glasgow
gives, the denominator was relatively easy
to ascertain (e.g., all diabetic patients, all
diabetic patients 75 years of age, all di-
abetic patients using insulin). However,
since only smokers would be eligible for
smoking cessation counseling, we needed
a good estimate of the denominator (the
number of smokers), which was not avail-
able in our dataset. As can be seen in Table
1 of our article (2), documentation of cur-
rent smoking was only present for 23 pa-
tients in the baseline audit. This 8% rate is
far below estimates of smoking in the state
of Indiana, and was felt to be too unstable
a denominator to allow meaningful fol-
low-up of interventions targeted at the
numerator.
Second, Dr. Glasgow feels that group-
based educational sessions on predeter-
mined topics were doomed to fail. Our
sessions for the lay public were highly in-
teractive, well attended, and linked tem-
porally to the physician sessions. Not all
studies have shown that group education
performs less well than individualized in-
struction (3), but we agree that there are
more potent patient education interven-
tions than those we used in our study.
However, interventions such as nurse-
based self-management training or proac-
tive phone counseling are costly to initiate
and sustain. In closed systems such as
Kaiser Permanente or the Veterans Af-
fairs, in which the payor theoretically will
recoup the savings that ensue from im-
proved patient self-management, there is
an incentive to fund such programs (al-
though, interestingly, they are still rare).
Unfortunately, in the amorphous health
care system we studied, which is not atyp-
ical for much of the U.S., no organized
force exists to develop and fund such in-
terventions. We sought to make our inter-
ventions less costly and translatable to
current systems that do not have funds for
nurse case managers or one-on-one edu-
cation with each high-risk subject.
We agree that there is a need to ask
hard translational questions and to search
for innovative solutions to the “quality
chasm.” Solutions will vary depending
upon the resources available in the local
environment. It is evident that these are
not simple problems or they would have
been solved by now.
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